GRI Bio Stock Price, News & Analysis

GRI Bio (NASDAQ: GRI) has successfully closed its previously announced public offering, raising $5.0 million in gross proceeds. The offering included 1,388,888 shares of common stock along with three series of warrants (E-1, E-2, and E-3) at a combined price of $3.60 per share.

The warrants, exercisable immediately at $3.20 per share, have varying expiration periods: Series E-1 expires in 5 years, Series E-2 in 18 months, and Series E-3 in 9 months. If fully exercised, these warrants could generate additional gross proceeds of $13.3 million.

H.C. Wainwright & Co. served as the exclusive placement agent. The biotechnology company, focused on developing Natural Killer T cell modulators for inflammatory, fibrotic and autoimmune diseases, plans to use the net proceeds for product candidate development, working capital, and general corporate purposes.

GRI Bio (NASDAQ: GRI) has announced the pricing of a $5.0 million public offering consisting of 1,388,888 shares of common stock (or equivalents) and three series of warrants. The offering is priced at $3.60 per share with accompanying Series E-1, E-2, and E-3 warrants.

The warrants have an exercise price of $3.20 per share, with varying expiration periods: Series E-1 expires in 5 years, Series E-2 in 18 months, and Series E-3 in 9 months. If fully exercised, the warrants could generate additional gross proceeds of $13.3 million.

The offering, managed by H.C. Wainwright & Co. as exclusive placement agent, is expected to close around April 2, 2025. The company plans to use the proceeds for product candidate development, working capital, and general corporate purposes.

GRI Bio (NASDAQ: GRI) has reported encouraging interim safety results from its ongoing Phase 2a study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) treatment. The Independent Data Monitoring Committee recommended continuing the study as planned, with no safety concerns identified in the first 12 patients evaluated.

The study evaluates GRI-0621, a RAR-βɣ dual agonist administered at 4.5mg orally once daily. Initial results show the drug is safe and well-tolerated, with no hyperlipidemia observed in the assessed patients. The Phase 2a trial will enroll approximately 36 subjects in a 2:1 ratio (GRI-0621 vs. placebo) for a 12-week treatment period.

The study's primary endpoint focuses on safety and tolerability, with secondary endpoints including changes in serum biomarkers and pharmacodynamic activity. Interim biomarker data is expected in Q2 2025, with topline results anticipated in Q3 2025.

GRI Bio (NASDAQ: GRI) has strengthened its intellectual property portfolio with two significant patent grants in Europe and Japan. The European patent covers GRI-0803, a novel activator of type 2 diverse NKT cells being developed for autoimmune disorders, particularly systemic lupus erythematosus. The Japanese patent focuses on methods for modulating dNKT and iNKT cells in treating inflammatory conditions through Retinoic Acid Receptor agonists.

The company's lead program, GRI-0621, is currently in a Phase 2a clinical trial for idiopathic pulmonary fibrosis (IPF). Interim data is expected in Q2 2025, with topline results anticipated in Q3 2025. The study is designed as a randomized, double-blind, multi-center, placebo-controlled trial.

GRI Bio (NASDAQ: GRI) announced its President and CEO Marc Hertz's participation in a Virtual Investor CEO Connect segment. During the presentation, Dr. Hertz discussed the company's lead program, GRI-0621, which targets Idiopathic Pulmonary Fibrosis (IPF), a rare chronic progressive fibrosing interstitial lung disease with treatment options.

The company highlighted upcoming milestones, including interim data expected at the beginning of next quarter and topline data in the subsequent quarter. The presentation is now available for viewing online through Virtual Investor's platform.

GRI Bio (NASDAQ: GRI) has reported its financial results for fiscal year 2024 and provided updates on its lead program GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) treatment. The company anticipates key data readouts in 2025, with interim data expected in Q2 and topline results in Q3 from its Phase 2a biomarker study.

Financial highlights include:

• Net loss of $8.2 million for 2024
• R&D expenses increased to $3.8 million from $3.2 million in 2023
• G&A expenses decreased to $4.5 million from $8.2 million in 2023
• Cash position of $5.0 million as of December 31, 2024

Recent achievements include presenting positive preclinical data showing GRI-0621 reduces inflammatory and fibrotic drivers in IPF, and receiving a European patent for GRI-0803. The company's cash runway is expected to fund operations into Q2 2025.

GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, has announced regaining compliance with Nasdaq's minimum bid price rule. The company received official notice from Nasdaq on March 10, 2025, confirming its compliance with Listing Rule 5550(a)(2).

GRI Bio (NASDAQ: GRI) has announced a 1-for-17 reverse stock split, effective February 21, 2025, at 4:01 p.m. Eastern Time. The company's common stock will begin trading on a split-adjusted basis on February 24, 2025, under the same ticker symbol 'GRI' but with a new CUSIP number.

The reverse split aims to increase the per share trading price to regain compliance with Nasdaq's minimum bid price requirement. The split will reduce outstanding shares from approximately 8,933,366 to 525,492. Proportional adjustments will be made to exercise and conversion prices of outstanding stock options, warrants, and convertible securities.

No fractional shares will be issued; stockholders will receive cash payments for fractional shares. Stockholders with electronic book-entry shares require no action, while those holding physical certificates will receive instructions from Broadridge Corporate Issuers Solutions for exchanging certificates.

GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in the Virtual Investor "Top 5 for '25" On-Demand Conference. The company's CEO, Marc Hertz, Ph.D., presented the top five reasons why investors and industry colleagues should watch GRI Bio in 2025. The presentation is available for viewing on the company's website and through the conference platform.